Current management of stage IV nasopharyngeal carcinoma without distant metastasis

Wai Tong Ng, June Corry, Johannes A Langendijk, Anne W M Lee, Antti Mäkitie, William M Mendenhall, Alessandra Rinaldo, Juan P Rodrigo, Nabil F Saba, Robert Smee, Primož Strojan, Carlos Suárez, Jan B Vermorken, Alfio Ferlito

Research output: Contribution to journalReview articlepeer-review

2 Citations (Scopus)

Abstract

Up to one in four patients with nasopharyngeal carcinoma present with non-metastatic stage IV disease (i.e. T4 or N3). Distinct failure patterns exist, despite the routine adoption of contemporary treatment modalities such as intensity modulated radiotherapy and systemic chemotherapy. Concurrent chemoradiotherapy (CCRT) followed by adjuvant chemotherapy or induction chemotherapy followed by CCRT are commonly employed in this setting, with the latter emerging as the preferred option. Additionally, emerging radiation technologies like proton therapy has become available offering new opportunities for prevention of radiation-induced side effects. This article reviews not only the current treatment strategies, but also discusses novel ways to tackle this challenging disease with respect to the patterns of failure.

Original languageEnglish
Article number101995
Number of pages10
JournalCANCER TREATMENT REVIEWS
Volume85
Early online date21-Feb-2020
DOIs
Publication statusPublished - Apr-2020

Keywords

  • Nasopharyngeal carcinoma
  • Prognosis
  • Radiotherapy
  • Chemotherapy
  • Targeted therapy
  • Immunotherapy
  • INTENSITY-MODULATED RADIOTHERAPY
  • PHASE-II TRIAL
  • QUALITY-OF-LIFE
  • CONCURRENT CHEMORADIOTHERAPY
  • ADJUVANT CHEMOTHERAPY
  • INDUCTION CHEMOTHERAPY
  • RANDOMIZED-TRIAL
  • RADIATION-THERAPY
  • ANTITUMOR-ACTIVITY
  • DOSIMETRIC CHANGES

Cite this